About us

Who we are ?

About Alesta Therapeutics

Alesta Therapeutics is a pioneering company based in Leiden, Netherlands, dedicated to the development of first-in-class small molecules that target GCN2. Our commitment to advanced, high-quality chemistry has led us to develop a clinical candidate with an extensive pre-GLP toxicology and CMC package. We are excited to announce that our GLP toxicology studies are set to launch in the third quarter of 2024.

Our work is focused on addressing a genetic subtype of Charcot-Marie-Tooth disease, a debilitating peripheral neuropathy. To achieve this, we are combining our in-house expertise with the knowledge of global academic and industry-leading experts. We are proud to collaborate with Professor Dr. Rob Burgess from the Jackson Laboratories, a renowned figure in this field.

Alesta Therapeutics was incorporated by Droia Ventures and is supported by a network of esteemed partners, including Thuja Capital, Praxis Biotech, and Casi Pharmaceuticals. Together, we are committed to advancing innovative treatments that can make a significant difference in the lives of patients.

Get in touch

Contact us for more information !

For inquiries or more information, please reach out to us. We’re here to help!

OUR team

Management team

Ilan Ganot

(Solid Bio)

CEO

Matthias Van Woensel
PhD

(Droia Ventures)

CSO

Jakub Swiercz
PhD

(iTeos, Epics)

VP R&D

Board of directors

Joe Vacca
PhD

(Chem MRL, Wuxi)

Head of Med Chem

Anu Gupta

Consultant PM

Alan Louette
Bac

(Root Agency)

Web Developer

Danny Burg
PhD

Consultant in Toxicology, D2Team

Julien Beyrath
PhD

Consultant Pre-clinical and Early Clinical, Development, Curare

Frank Hoke
PhD

Consultant in Clinical Pharmacology, OKI

Bernhard Paul
PhD

Consultant in CMC – Carinth

About Alesta Therapeutics

Contact us for more information !

Management team

Board of directors

Fill out the form below to apply for the role of About us